Back to search

Boston University

The role of sequence variations in cancer

Abstract

dc:description.abstract

Cancer regulation is a multi-layered process driven not only by mutations in protein-coding sequences, but also by epigenetic modifications, chromatin accessibility, and sequence variations in regulatory regions that rewire gene expression programs. While promoter mutations have traditionally been studied for their effects on transcriptional output, their impact on post-transcriptional regulation remains poorly understood. In this dissertation, I investigate how sequence variations in promoter regions influence transcription, alternative splicing, and downstream cellular phenotypes in cancer. Focusing on cancer-associated promoter point mutations, I demonstrate that single-nucleotide changes within promoter regions can significantly alter alternative splicing outcomes in conjunction with changes in gene expression. Using bichromatic reporter assays, I functionally characterize promoter mutations in cancer-relevant genes and uncover a coupling between promoter sequence variation and splicing regulation. I further show that these splicing defects can be therapeutically modulated using antisense oligonucleotides and CRISPR-based strategies, highlighting regulatory sequence variation as a tractable therapeutic target. To place these findings in a broader regulatory context, I integrate large-scale protein-DNA interaction networks that map transcription factor binding, cooperativity, and antagonism across cancer promoters, demonstrating how transcription factors interpret regulatory sequence to shape gene expression programs. I extend this framework to show how transcription factors regulate gene expression with multiple layers of specificity and how transcription factor fusion proteins rewire DNA-binding landscapes in cancer. Collectively, this work establishes regulatory sequence variation as a multi-layer driver of transcriptional and post-transcriptional dysregulation in cancer, identifies promoter mutations as functional modulators of alternative splicing, and highlights both CRISPR-based and RNA-targeted therapeutic strategies capable of correcting aberrant gene regulation. These findings broaden the functional interpretation of non-coding cancer mutations and provide new insights for precision cancer therapeutics.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Biology
Grantor
Boston University
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Lu, Yunwei
Advisors dc:contributor.advisor
  • Fiszbein, Ana
  • Fuxman Bass, Juan

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/53586

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Lu, Yunwei. The role of sequence variations in cancer. doctoral thesis, Boston University, 2026. https://hdl.handle.net/2144/53586